| 1. |
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Cohen, O., et al.
(author)
-
COST-EFFECTIVENESS ANALYSIS OF THE MINIMED (TM) 780G SYSTEM VERSUS MULTIPLE DAILY INJECTIONS WITH INTERMITTENTLY SCANNED CONTINUOUS GLUCOSE MONITORING IN INDIVIDUALS WITH TYPE 1 DIABETES IN SWEDEN
- 2021
-
In: Diabetes Technology & Therapeutics. - : Mary Ann Liebert. - 1520-9156 .- 1557-8593. ; 23:Suppl. 2, s. A81-A81
-
Journal article (other academic/artistic)abstract
- Background and Aims: Type 1 diabetes (T1D) therapy is continually evolving and Advanced Hybrid Closed Loop (AHCL) insulin pump systems and intermittently scanned continuous glucose monitoring (IS‐CGM) are emerging as the standard of care for many individuals with T1D. The objective of this analysis was to assess the cost‐effectiveness of the MiniMedTM 780G AHCL system versus IS‐CGM plus multiple daily injections of insulin (MDI) or continuous subcutaneous insulin infusion (CSII) in adults with T1D in Sweden.Methods: The analysis was performed using the IQVIA CORE Diabetes Model and clinical input data were sourced from observational studies. Simulated patients were assumed to have a baseline HbA1c of 7.8% (62 mmol/mol)[1] and use of the MiniMed™ 780G system was assumed to reduce HbA1c by 0.5%.[2] The analysis was performed from a societal perspective over a lifetime time horizon. Future costs and clinical outcomes were discounted at 3% per annum.Results: The MiniMedTM 780G system was associated with a quality‐adjusted life‐year (QALY) gain of 1.946 but generated higher overall costs versus MDI/CSII+IS‐CGM, leading to an incremental cost‐effectiveness ratio of SEK 373,700 (€ 36,857.80) per QALY‐gained. MiniMedTM 780G system use resulted in a lower cumulative incidence of diabetes‐related complications. Higher acquisition costs were partially offset by reduced complications costs. Extensive sensitivity analysis on key drivers confirmed the robustness of results.Conclusions: For the lifetime of adults with long‐standing T1D based in Sweden, use of the MiniMed™ 780G system is projected to be cost‐effective when compared with IS‐CGM plus MDI/CSII.
|
|
| 5. |
- Gonzalez-Ortiz, Fernando, et al.
(author)
-
A novel ultrasensitive assay for plasma p-tau217: performance in individuals with subjective cognitive decline and early Alzheimer's disease.
- 2023
-
In: medRxiv : the preprint server for health sciences.
-
Journal article (other academic/artistic)abstract
- Detection of Alzheimer's disease (AD) pathophysiology among cognitively unimpaired individuals and those experiencing subjective cognitive decline (SCD) remains challenging. Plasma p-tau217 is one of the most promising of the emerging biomarkers for AD. However, accessible methods are limited.We employed a novel p-tau217 immunoassay (UGOT p-tau217) in four independent cohorts (n=308) including a cerebrospinal fluid (CSF) biomarker-classified cohort (Discovery), two cohorts consisting mostly of cognitively unimpaired participants (MYHAT and Pittsburgh), and a population-based cohort of individuals with SCD (β-AARC).UGOT p-tau217 showed high accuracy (AUC= 0.80-0.91) identifying Aβ pathology, determined either by Aβ positron emission tomography or CSF Aβ42/40 ratio. In individuals experiencing SCD, UGOT p-tau217 showed high accuracy identifying those with a positive CSF Aβ42/40 ratio (AUC= 0.91).UGOT p-tau217 can be an easily accessible and efficient way to screen and monitor patients with suspected AD pathophysiology, even in the early stages of the continuum.
|
|
| 6. |
|
|
| 7. |
- Jendle, J, 1963-, et al.
(author)
-
COST-EFFECTIVENESS ANALYSIS OF THE MINIMED (TM) 780G SYSTEM VERSUS MULTIPLE DAILY INJECTIONS WITH INTERMITTENTLY SCANNED CONTINUOUS GLUCOSE MONITORING IN INDIVIDUALS WITH TYPE1 DIABETES ACROSS EUROPE
- 2023
-
In: Diabetes Technology & Therapeutics. - : Mary Ann Liebert. - 1520-9156 .- 1557-8593. ; 25:Suppl. 2, s. A119-A119
-
Journal article (other academic/artistic)abstract
- Background and Aims: The standard of care for people with type 1 diabetes (T1D) is continually evolving and Automated Insulin Delivery system (AID) systems and continuous glucose monitoring (CGM) are emerging as the standard of care for many individuals with T1D. This study aimed to compare the long-term cost-effec-tiveness of the MiniMedTM 780G system versus MDI+ intermittently scanning CGM in people with T1D across European countries.Methods: Long-term costs and clinical outcomes were estimated using the CORE Diabetes Model. Clinical data were derived from ADAPT, prospective, multicentre, open-label, randomized control trial [1]. MiniMedTM 780G system was associated with a reduction in HbA1c of 1.54%, from 9.04% (75 mmol/mol) at baseline to 7.5% (58 mmol/mol) at the end oft he study; isCGM was associated with a reduction in HbA1c of 0.2%1. Quality of life benefits associated with a reduced fear of hypoglycaemia were also applied. Analyses were conducted in Sweden and other countries across Europe.Results: The MiniMedTM 780G system was associated with aquality-adjusted life-year (QALY) gain of 2.24 with higher overall costs versus MDI+isCGM, leading to an incremental cost-effectiveness ratio of SEK 366,919 (33,757 Euro) per QALY-gained. MiniMedTM 780G system resulted in a lower cumulative incidence of diabetes-related complications. Higher acquisition costs were partially offset by reduced complications costs. Extensive analysis of key drivers and analysis conducted across different countries confirmed the robustness of the results.Conclusions: Over patient lifetimes, for adults with T1D, the use of the AID system is projected to be cost-effective when compared with MDI+isCGM.1. Choudhary P, et al. Lancet Diabetes Endocrinol 2022 https://doi.org/10.1016/S2213-8587(22)00212-1.
|
|
| 8. |
|
|
| 9. |
- Segal, Eran, et al.
(author)
-
Building an international consortium for tracking coronavirus health status
- 2020
-
In: Nature Medicine. - : Springer Science and Business Media LLC. - 1078-8956 .- 1546-170X. ; 26:8, s. 1161-1165
-
Journal article (other academic/artistic)abstract
- We call upon the research community to standardize efforts to use daily self-reported data about COVID-19 symptoms in the response to the pandemic and to form a collaborative consortium to maximize global gain while protecting participant privacy.
|
|
